(S)-2-<oxy>-6-<<(phenylmethoxy)carbonyl>amino>hexanoic acid | 107492-16-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-<oxy>-6-<<(phenylmethoxy)carbonyl>amino>hexanoic acid
• 英文别名: (S)-2-[[Hydroxy(4-phenylbutyl)phosphinyl]oxy]-6-[[(phenylmethoxy)carbonyl]amino]hexanoic acid；(S)-2-{[hydroxy(4-phenylbutyl)phosphinyl]oxy}-6-{[(phenylmethoxy)carbonyl]amino}hexanoic acid；(2S)-2-[hydroxy(4-phenylbutyl)phosphoryl]oxy-6-(phenylmethoxycarbonylamino)hexanoic acid
• CAS: 107492-16-0
• 化学式: C₂₄H₃₂NO₇P
• 分子量: 477.494
• InChiKey: QDIKXRHBUYRRON-QFIPXVFZSA-N

物化性质

• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (S)-2-<oxy>-6-<<(phenylmethoxy)carbonyl>amino>hexanoic acid 在 palladium dihydroxide 氢气 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 13.0h， 生成 西罗普利
  参考文献：
  名称：

  A highly convergent preparation of phosphonyloxyacylamino acids:

  摘要：

  DOI：

  10.1016/s0040-4039(00)85232-6
• 作为产物：
  描述：

  {4-[(S)-2,5-Dioxo-2-(4-phenyl-butyl)-2λ5-[1,3,2]dioxaphospholan-4-yl]-butyl}-carbamic acid benzyl ester 在 水 作用下， 以 四氢呋喃 为溶剂， 生成 (S)-2-<oxy>-6-<<(phenylmethoxy)carbonyl>amino>hexanoic acid
  参考文献：
  名称：

  A highly convergent preparation of phosphonyloxyacylamino acids:

  摘要：

  DOI：

  10.1016/s0040-4039(00)85232-6

文献信息

• Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04616005A1

  公开（公告）日：1986-10-07

  Phosphonyl hydroxyacyl amino acids of the formula ##STR1## wherein X is a substituted or unsubstituted imino or amino acid or ester. These compounds possess angiotensin converting enzyme activity and are thus useful as hypotensive agents.

  磷酰羟基酰氨基酸的化学式为##STR1##其中X是取代或未取代的亚胺或氨基酸或酯。这些化合物具有血管紧张素转换酶活性，因此可用作降压剂。
• Phosphonate substituted amino or imino acids useful as antihypertensives
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0414190A2

  公开（公告）日：1991-02-27

  This invention is directed to new phosphonate substituted amino or imino acids of the formula isomeric mixtures thereof and pharmaceutically acceptable salts thereof, wherein: X is an imino or amino acid of the formula or which show hypotensive activity.

  本发明涉及新的膦酸盐取代的氨基或亚氨基酸，其式为 其异构体混合物及其药学上可接受的盐，其中X 是式中的亚氨基或氨基酸 或 具有降血压活性。
• (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme. 2. Terminal amino acid analogs of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline
  作者：Donald S. Karanewsky、Michael C. Badia、David W. Cushman、Jack M. DeForrest、Tamara Dejneka、Ving G. Lee、Melanie J. Loots、Edward W. Petrillo

  DOI：10.1021/jm00167a028

  日期：1990.5

  Analogues of (S)-1-[6-amino-2[[hydroxy(4-phenylbutyl)phosphinyl] oxy]-1-oxohexyl]-L-proline (1, SQ 29,852) in which the terminal proline residue has been replaced by a variety of substituted and heteroatom-substituted prolines, N-arylglycines, N-cycloalkylglycines, and bicyclic amino acids have been synthesized and evaluated as inhibitors of angiotensin converting enzyme in vitro and in vivo. In general, the addition of lipophilic substituents to the 4-position of proline of the parent phosphonate 1 resulted in substantial increases in in vitro activity. The largest improvements were observed in the case of cis-benzyl (36-fold) and dithioketal (24-fold) analogues 2r and 2x, respectively. These enhancements of in vitro activity were accompanied by modest increases (2-3.5-fold) in in vivo (iv) activity. Among the various terminal amino acid replacements examined in this study, the indoline-based analogue 2i was by far the most potent compound on iv administration in the normotensive rat.
• KARANEWSKY, DONALD S.;BADIA, MICHAEL C.;CUSHMAN, DAVID W.;DEFORREST, JACK+, J. MED. CHEM., 33,(1990) N, C. 1459-1469
  作者：KARANEWSKY, DONALD S.、BADIA, MICHAEL C.、CUSHMAN, DAVID W.、DEFORREST, JACK+

  DOI：——

  日期：——
• TAOTTATHIL, JOHN K.
  作者：TAOTTATHIL, JOHN K.

  DOI：——

  日期：——